CN Patent

CN113490528B — 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途

Assigned to Novartis AG · Expires 2024-12-03 · 1y expired

What this patent protects

本披露提供了具有式(I)的化合物：或其药学上可接受的盐、水合物、溶剂化物、前药、立体异构体、或互变异构体，其中R 1 、R 2 、R 3 、R x 、和n是如本文所定义的；及其制造和使用方法。

USPTO Abstract

本披露提供了具有式(I)的化合物：或其药学上可接受的盐、水合物、溶剂化物、前药、立体异构体、或互变异构体，其中R 1 、R 2 、R 3 、R x 、和n是如本文所定义的；及其制造和使用方法。

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN113490528B
Jurisdiction: CN
Classification: —
Expires: 2024-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.